Why the study?
Rivaroxaban has low water solubility that limits oral bioavailability, and limited practical studies have explored strategies to enhance its bioavailability for industrial use.
This review highlights seven pharmaceutical formulation strategies to overcome the low water solubility and improve the oral bioavailability of the anticoagulant rivaroxaban.
Answers are grounded in this paper and cite their sources.
These strategies require clinical validation before any prescribing changes; leaves open targeted trials to confirm bioavailability gains.
This review article discusses Rivaroxaban (RXB), an anticoagulant that has gained much attention due to its ability to prevent blood clots from forming in the body. However, one of the major challenges pharmaceutical companies face is the low water solubility of RXB, which can lead to difficulties in formulating the drug for oral administration and affect the drug's bioavailability. However, to the best of our knowledge, limited studies have explored enhancing the bioavailability of the RXB. Most of these studies have been purely academic and impractical for industrial use. Therefore, this review article aims to discuss successful studies that have increased the bioavailability of RXB. The goal is to inspire researchers to develop this new drug further. The article covers seven strategies for enhancing the bioavailability of RXB, including microspheres, liposomes, self-nano emulsifying drug delivery system, solid lipid nanoparticles, cocrystals, sustained release, and solid dispersion. The studies discussed in this review offer valuable insights into developing novel drug delivery systems that can help overcome the limitations of existing drugs.
No takes yet. Share an insight, caveat, or question.
Al-Shoubki et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: